Breast Cancer Clinical Trial
Official title:
Omega 3 Fatty Acids and Breast Cancer Prevention: Protective Benefits of Increased Fish Consumption
Research studies show that the type of fat in the diet may affect breast cancer risk. Fish
oil and fish contain increased amounts of omega 3 fatty acids which appear to stop or slow
down the growth and development of breast cancer cells in laboratory studies of mice and
breast cancer cells. The use of omega 3 fatty acids to reduce the risk of breast cancer
development in humans has not been adequately studied. Eating fish or taking fish oil may
increase the amount of omega 3 in the breast, which may lower one's risk of breast cancer
development.
Persons in this study with do one of the following: (1) take two capsules daily of omega 3
fatty acid supplements, or (2) eat several servings of canned salmon / tuna per week for a
total of three months. Amounts of omega 3 fatty acids in the body's tissues will be measured
by blood tests and a small sample of breast fat as obtained by a fine needle aspiration.
This study is supported by funding from the National Fisheries Institute, Food Innovation
Center of The Ohio State University, and The Ohio State University Comprehensive Cancer
Center.
The primary objectives of this study are to:
i.) Determine the effects of increased fish consumption on serum and breast fat tissue fatty
acids in women at high risk for developing breast cancer relative to an omega 3 fatty acid
supplement;
ii.) Assess adherence and tolerability of increased dietary intake of fish relative to an
omega 3 fatty acid supplement.
Secondary objectives include:
iii.) Evaluate possible correlations between physical factors such as body mass index (BMI)
and dietary factors and target tissue effects.
iv.) Explore additional biomarkers as surrogate endpoints to measure effects of fish
consumption.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |